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Abstract  
Introduction: Although DOACs do not require regular measurements of their blood concentrations, clinical 
situations may require an assessment of their concentration. Among the factor Xa inhibitors, edoxaban is the only 
compound for which some metabolites (e.g. edoxaban-M4) are reported to be pharmacologically active. Therefore, 
their contribution could interfere with assays used for the estimation of edoxaban concentration. In addition, drug 
interactions may alter the metabolite/parent compound ratio making the sole estimation of edoxaban concentration, 
a poor assessment of the overall anticoagulation. 
Aims: To develop a validated UHPLC-MS/MS method to quantify simultaneously edoxaban and its more relevant 
M4-metabolite in human plasma. 
Methods: Electrospray ionization and chromatographic separation were optimized for the simultaneous dosage of 
edoxaban and edoxaban-M4. The method was validated according to regulatory guidelines for bioanalytical 
method validation. 
Results: The total run time was 6 minutes. The method was validated for calibration curves, precision, accuracy, 
carry-over, selectivity, matrix effect and short-time stability. 
Conclusion: This method permits quantification of edoxaban and edoxaban-M4 providing complementary 
information about the inhibitory effect of this active metabolite in chronometric or chromogenic assays. Although 
patients treated with edoxaban exhibits usually low concentrations of active metabolites, the measurement of 
edoxaban-M4 is interesting; especially in case of drug interactions. Indeed, concomitant prescriptions of edoxaban 
and carbamazepine or rifampicin is frequent and may lead to disturbance of the estimations of edoxaban 
concentration by chromogenic anti-Xa assays. Therefore, patients are at risk of having inadequate control of 
anticoagulation supporting the need of measuring the most representative edoxaban metabolite concomitantly to 
the parent compound. 
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Abbreviations 
%Dev Percentage of relative standard deviation 
CV Coefficient of variation 
DMSO Dimethyl sulfoxide 
DOACs Direct oral anticoagulants 
EMA European Medicines Agency 
ESI Electro spray ionization 
ESI+ Electro spray on positive ionization mode 
FDA Food and Drug Administration 
ICH International Council of Harmonization 
IS Internal standard 
LC Liquid chromatography 
LLOQ Lower limit of quantification 
ME Matrix effect 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
NPP Normal pooled plasma 
PBS Phosphate buffer saline 
PPP Platelet poor plasma 
QCs Quality controls 
UHPLC-MS/MS Ultra-high-performance liquid chromatography coupled with mass 
spectrometry 
ULOQ Upper limit of quantification 
VKAs Vitamin K antagonists 
VTE Venous thromboembolisms 
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1. Introduction  
To date, ultra-high-performance liquid chromatography coupled with mass spectrometry (UHPLC-MS/MS) is 
quite expensive and time consuming, and thus measurements of DOACs have been performed with chromogenic 
FXa- or FIIa-based assays [1-8]. These tests initially responded to the clinical need by providing good sensitivity, 
high reproducibility and a short turn-around time [3]. Nevertheless, such tests are not able to discriminate between 
the inhibitory effect of the parent compounds and its metabolite which can become clinically relevant as already 
demonstrated with dabigatran and its acylglucuronide metabolite [9]. While apixaban and rivaroxaban do not have 
active metabolites, this is not the case for edoxaban [10]. Edoxaban received its market authorisation in Europe in 
June 2015 under the brand name of Lixiana for the prevention of stroke and systemic embolism in patients with 
non-valvular atrial fibrillation as well as for the treatment of venous thromboembolisms (VTE) and pulmonary 
embolism (PE) [5]. Edoxaban has the particularity to release active metabolites which could be present at a 
sufficient level in the blood to have an impact on haemostasis. These metabolites are named edoxaban-M4, -M6 
and -M8 [11]. The metabolism occurs through carboxylesterase-1 (CES-1), cytochrome P450 3A4/5 (CYP3A4/5) 
and non-enzymatic hydrolysis [12]. Although DOACs do not require regular measurements of their blood 
concentrations, clinical situations may require an assessment of their concentration (detection of drug 
accumulation in acute renal or hepatic failure; planning the timing of urgent invasive procedure; recurrence of 
stroke or bleedings). Currently, prothrombin time (PT) or activated partial thromboplastin time (aPTT) 
measurement are proposed for the estimation of the intensity of some DOAC.  Nevertheless, theses assays are 
strongly impacted by inter-reagent and inter-individual variability and must not be used in first intention to assess 
the intensity of anticoagulation with DOACs [5]. Current chromogenic tests for edoxaban are calibrated with 
standards containing 3 or 4 different levels of edoxaban. However, these standards do not include or consider 
active metabolites. This approach is questioning since, according to the Food and Drug Administration (FDA) 
guideline on Bioanalytical Validation [13], a validated method should meet the acceptance criteria regarding 
selectivity and specificity. Chromogenic anti-Xa assays have been reported to be sensitive to the presence of the 
M4-metabolite [14] and thus, the specificity criteria is certainly an issue. Normally, the assay should be free of 
potential interfering substance including metabolites [13]. This lack of specificity could lead to overestimation or 
underestimation of edoxaban concentrations depending on the clinical situation. Namely, the inhibitory constant 
(Ki) of these metabolites is not the same as the parent compound and thus, depending on the parent/metabolite 
ratio, the inhibitory effect on functional assay, like chromogenic anti-Xa assay, for a same initial amount of 
edoxaban may differ. Therefore, there is a need to develop sensitive and specific assays for edoxaban [3, 5]. 
 5 
In this context, we developed a validated UHPLC-MS/MS method to measure concentration of edoxaban and its 
active major metabolite-M4 in human plasma [13, 15]. 
2. Material and Methods 
2.1. Preparation of the Normal Pooled Plasma (NPP) 
Sixty individuals were included in the study. The exclusion criteria were thrombotic and/or hemorrhagic events, 
antiplatelet and/or anticoagulant medication, pregnancy and uptake of drugs potentially affecting the platelet 
and/or coagulation factor functions during the two weeks prior to the blood drawn. The study protocol is in 
accordance with the Declaration of Helsinki and has been approved by the Ethical Committee of the CHU UCL 
Namur, Yvoir, Namur, Belgium (B03920096633). Blood was taken by venipuncture in the antecubital vein and 
collected into 0.109M sodium citrate (9:1 v/v) tubes (Vacuette®, Greiner Bio-One International, Kremsmünster, 
Austria) using a 21-gauge needle (Terumo, Leuven). The platelet poor plasma (PPP) was obtained from the 
supernatant fraction of blood tubes after a double centrifugation for 15 minutes at 2,500g at room temperature. 
Immediately after centrifugation, PPP from the 60 donors were brought together to obtain the NPP which was 
frozen at -80°C without any delay. Treatment of plasmas by proteins precipitation was performed within 4 hours 
after thawing [5].  
2.2. Instrumentation and analytical conditions 
All optimized parameters and protocol are provided in supplementary material (Supplementary material and 
Supplementary figures 1-2).  
2.3. Method validation 
2.3.1. Calibration curve 
Calibration curves were constructed from 3 to 500ng/mL for edoxaban and from 3 to 150ng/mL for edoxaban-M4 
with six levels of non-zero concentration standards [13, 15]. Calibration ranges were chosen to cover (supra)-
therapeutic ranges for edoxaban and edoxaban-M4. Calibration standards were run in triplicate in consecutive 
runs. The calibration curves were fitted using a weighted least-squares non-linear regression method by measuring 
the peak-area ratio of the analytes to the internal standard (IS). The acceptance criterion for each back-calculated 
standard concentration was ± 15% deviation from the nominal value, except for the lower limit of quantification 
(LLOQ), for which a deviation of ± 20% was permitted. 
2.3.2. Precision and accuracy 
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The intra-day precision and accuracy of the assay were estimated by analysing in a single run of 3 replicates of 
each QC within 1 day. The inter-day precision and accuracy were assessed by repeating the analysis of three 
concentration levels of QC samples on 5 consecutive days. Accuracy was expressed as a percentage of relative 
standard deviation (%Dev), while the precision was expressed as the coefficient of variation (%CV). The accuracy 
and precision were required to be within a ±20% range for LLOQ and within a ±15% for higher concentrations of 
edoxaban. For edoxaban-M4 measurement, accuracy and precision were required to be within a ±25% range for 
LLOQ and within a ±20% for higher concentrations [13, 15]. 
2.3.3. Carry-over 
The carry-over of analytes and IS were evaluated by injecting a blank sample immediately after a sample of upper 
limit of quantification. Carry-over should not exceed 20% of the signal of the LLOQ for analytes and 5% for IS 
[13, 15]. 
2.3.4. Lower limit of quantification 
The LLOQ was defined as the lowest concentration of edoxaban or edoxaban-M4 that could be quantitatively 
determined with acceptable precision and accuracy. Acceptance limits were defined as accuracy of 80-120% and 
precision ≤20%. 
2.3.5. Selectivity 
Selectivity was evaluated using six independent blank human plasmas to confirm the absence of potential 
interfering substances in the matrix [13, 15]. Chromatograms were visually compared with the corresponding 
spiked plasma.  
2.3.6. Specificity 
Specificity was assessed to ensure that the method is free of interference due potential residual molecules (e.g. 
other anticoagulants) [13, 15]. Measurements of spiked samples with 100ng/mL apixaban, edoxaban, edoxaban-
M4, rivaroxaban and dabigatran were performed in a single run to assess the potential interference by cross-
reacting molecules. 
2.3.7. Matrix effect (ME%) 
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To evaluate ME%, intermediate solutions were post-spiked in water or serum and compare with intermediate 
solutions post-spiked in NPP. The use of serum as alternative matrix is often encountered in clinical trials and the 
assessment of this matrix effect may inform on the possibility to perform the measurement in serum if needed.  
2.3.8. Extraction recovery 
Extraction recovery was determined by spiking known amounts of edoxaban, edoxaban-M4 and IS into NPP and 
into the extracted NPP and exposing the spiked NPP to the extraction procedure.  
2.3.9. Short time stability 
Edoxaban and edoxaban-M4 stability was assessed using QCs samples. Intermediate solutions of QCs were stored 
at -20°C and 4-7°C and plasmatic solutions were stored at -80°C and analysed on day 0 and after one month. 
Solutions were considered to be stable when average measured concentrations were within the limit of 80-120% 
of the nominal concentrations [13, 15]. 
2.4. Statistical analysis 
The UHPLC-MS/MS calibration curve was performed using a non-linear regression with a weighting function of 
1/x. Statistical analyses and graphics were computed using GraphPad Prism 5.0D® for Mac OS X. 
3. Results 
3.1. Optimization of the UHPLC-MS/MS method 
MS detection parameters were optimized by direct infusion of the reference compounds using the electrospray 
interface in the positive mode for edoxaban and edoxaban-M4 (Table 1). Selection of chromatographic 
conditions was optimized to suit an effective chromatographic resolution of analytes with symmetrical peak 
shapes, short retention time and overall short run time. 
3.2. Method validation of the UHPLC-MS/MS method 
3.2.1. Calibration curves, linearity and lower limit of quantification 
According to results reported in  Supplementary figure 3, non-zero calibrators were between ±15% of nominal 
concentrations and LLOQ were between ±20% of the nominal concentrations in each validation run. Although one 
calibration point is out of the range, 75% and a minimum of six non-zero calibrator levels meet the above criteria 
in each validation run [13, 15]. For routine purpose, the LLOQ was set at 3ng/mL for edoxaban and edoxaban-
M4.  
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3.2.2. Precision and accuracy 
Accuracy and precision obtained for inter-day and intra-day assays were within the limits of guidelines with 
calibration curves performed in NPP (Supplementary table 1 & Supplementary figures 4-7). 
3.2.3. Carry-over 
There was no detectable carry-over for analytes and IS even at high concentration (500ng/mL). 
3.2.4. Selectivity and specificity 
No co-eluting components peaks from endogenous or exogenous compounds were observed at the retention time 
of edoxaban, edoxaban-M4 and [2H6]-edoxaban (Supplementary figure 8 & 9). 
3.2.5. Matric effect (ME%) 
Non-relevant ME% (<15%) for edoxaban and IS were observed contrary to edoxaban-M4 measurements when 
these molecules were spiked in water. Serum matrix did not impact edoxaban and edoxaban-M4 measurements 
with our analytical method. 
3.2.6. Stability 
Stability of edoxaban and edoxaban-M4 was assessed for 28 days (-20°C) and for 155 days (4-7°C and -80°C). 
These compounds remained stable for the tested period and accuracy at each level was ±20% (some points are 
outside the range but represent less than 20% of all tested concentration levels) [13, 15].  
 
4. Discussion 
Although the scientific literature contains articles about liquid chromatography measurement of DOACs, few of 
them address the problem of the active metabolites and propose a simultaneous quantification of edoxaban and 
edoxaban-M4 in the same analytical run meeting criteria of the International Council of Harmonization (ICH), the 
European Medicines Agency (EMA) and FDA guidelines for ME, carry-over and stability [14, 16-18]. Our 
validation provides the pharmaceutical industries, the manufacturers and the physicians with a robust, sensitive 
and specific method for the measurement of edoxaban and its M4 metabolite.  
Despite this must-needed validation, some limitations of have to be recognized. This method allows the 
measurement of edoxaban and edoxaban-M4 concentration without considering edoxaban-M6. Nevertheless, 
regarding the IC50 (6.9nM) and the Cmax of edoxaban-M6 (8.55ng/mL), the impact on chromogenic assays should 
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be negligible contrary to the impact of the edoxaban-M4 which has a lower IC50 (1.8nM) and a higher Cmax 
(23.1ng/mL), in the absence of CYP inducers [10, 11, 19] in patients treated with edoxaban at 60mg once daily. 
Currently, no manufacturer has been able to offer us the edoxaban-M6 in sufficient quantity and with acceptable 
quality. Another limitation is that we only reported short time stability. Further investigations are underway to 
confirm the long-term stability of intermediate solutions of edoxaban/edoxaban-M4 and plasmatic solutions of 
analytes. 
The different pharmacodynamic profiles and the interest of measuring the active metabolites 
Among the factor Xa inhibitors, edoxaban is the only compound with pharmacologically active metabolites 
(edoxaban-M4, -M6 and -M8). These metabolites may contribute to the global anticoagulant activity and could 
interfere with chromogenic assays usually used for the estimation of the plasma level of edoxaban [5, 14]. Taking 
into consideration their respective IC50 towards human factor Xa, these metabolites would inhibit factor Xa at 
different degree. Namely the IC50 of edoxaban, and the metabolites-4 (M4; D21-2393), -6 (M6; D21-1402) and -
8 (M8; D21-2135) are 3.0, 1.8, 6.9 and 2.7nM, respectively (Figures 1 & 2) [10]. While these differences may 
only have a small impact in a population where the metabolic pathways are not inhibited or induced (the relative 
presence of edoxaban-M4 due to CES1 and edoxaban-M6 and -M8 due to CYP3A4/5 are less than 10% each [10]), 
the metabolite to parent ratio is increased in presence of inducers of CYP3A4/5 and P-gp. A potential interest of 
synchronously measuring edoxaban and edoxaban-M4 is to obtain complementary information about the impact 
of the active metabolite in chronometric or chromogenic assays.  
This validated method could be applicable in common clinical situation or situations requiring a close monitoring 
of edoxaban and its most active metabolite. This is especially important since at low concentration (<30ng/mL) a 
deviation of more than 50% has been observed (anti-Xa vs LC-MS/MS) [14], suggesting that anti-Xa assays are 
not able to provide reliable results in these low values. This becomes of clinical interest in light of the low edoxaban 
concentrations observed at CTrough in the various indications (Figure 3) [3, 20-22]. Also, such low concentrations 
(i.e. 30 or 50ng/mL) are threshold for decision making (i.e. before urgent surgery with high bleeding risk or to 
guide antidote administration) and any inaccuracy may lead to mismanagement or inappropriate clinical judgments 
[23]. 
The issue of drug interactions  
In addition, this technique could be interesting for adult population with drug-drug interactions which are 
frequently reported in the daily routine (e.g. co-treatment with quinidine, verapamil, ketoconazole, rifampin, …,) 
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[10, 12]. Indeed, pharmacokinetic interactions with edoxaban have already be highlighted, attesting that exposure 
to edoxaban and its active metabolites is significantly disturbed when edoxaban is administered with CYP3A4/5 
inducers (e.g. rifampin) or inhibitors (e.g. cyclosporine, erythromycin) [10, 12, 14, 19, 24, 25] (Table 2). For 
example, co-administration of rifampin and edoxaban leads to an increased concentration of edoxaban-M4 (23.1 
ng/mL without rifampin vs 108ng/mL with rifampin) which is not formed through the CYP3A4/5 pathway. 
According to Mendell et al. the increased concentration is linked to a potential induction of CES1 through 
upregulation of the pregnane X receptor gene and to the inhibitory effect of rifampin on organic anion transporting 
polypeptide 1B1 (OATP1B1) [19].  
Anti-epileptic agents are also frequently administered concomitantly with anticoagulant in the NVAF setting [26]. 
Indeed, the cause of symptomatic epilepsy due to strokes and cerebrovascular diseases is estimated to be at 30-
40% [27, 28]. With the exception of lamotrigine, pregabalin, zonisamide and lacosamide which have a safer 
pharmacokinetic profile, phenobarbital, phenytoin and carbamazepine may cause pharmacological interactions 
due to their impact on CYP3A4 and P-glycoprotein (P-gp) [28-30]. Although such drugs should be avoided, 
concomitant prescriptions of edoxaban and carbamazepine, first-intention treatment, still remains. Therefore, 
patients are at risk of exhibiting drug-drug interactions leading to inadequate control of the degree of 
anticoagulation or disturbed measurement of edoxaban concentration. This supports the need of measuring the 
most representative active metabolites according to special circumstances to known the real contribution of each 
compound in order to highlight abnormal edoxaban or metabolite levels [28-30]. 
To note, an interim analysis of our ongoing study (data not show) evaluating the impact of co-administration of 
cytochrome 3A4 inducers and edoxaban on edoxaban-M4/edoxaban ratios, demonstrates that the concentration of 
edoxaban-M4 is increased compared to patients without such interactions. This increase is more pronounced at 
low concentrations of edoxaban and leads to a significant increase of the ratio edoxaban-M4/edoxaban. Deviations 
between chromogenic anti-Xa assessments and mass spectrometry measurements appears to be high in those with 
drug interactions (i.e. > 20%). Investigations are planned to confirm and compare these results to other 
chronometric and chromogenic assays. 
To conclude, the evidence from the literature and the data reported in regulatory documents that have led to the 
marketing authorization of edoxaban [31, 32] questions about the suitability of calibrators that do not consider the 
usual proportion of the active metabolites when reporting results as edoxaban equivalent. 
5. Conclusion 
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In conclusion, this validated UHPLC-MS/MS method allows an accurate quantification of edoxaban and its active-
metabolite, edoxaban-M4, in human plasma according to the recommendations of the ICH, EMA and FDA. 
Calibration ranges permit simultaneous estimations of edoxaban and edoxaban-M4 concentrations in patient’s 
plasma. Although edoxaban treated patients exhibit usually low levels of active metabolites, some clinical 
situations may require an accurate estimation of the exposure for decision making. In addition, drug-drug 
interactions or hepatic insufficiency should stimulate investigations to explore abnormal levels of metabolites with 
different pharmacodynamic profile than edoxaban. Additional studies are needed to compared results obtained by 
this validated UHPLC-MS/MS method vs current coagulation/chromogenic assays in plasma from patients treated 
with edoxaban including those with drug interactions or with levels close to decision making thresholds. 
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Table 1: MS/MS parameters for edoxaban, edoxaban-M4 and corresponding internal standard 
Table 2: Non-exhaustive list of drug-drug interactions with edoxaban  
Figure legends 
Figure 1: Postulated edoxaban metabolism for active metabolites 
Figure 2: Chemical structure of edoxaban (DU-176b), edoxaban-M4 and internal standard ([2H6]-edoxaban) 





Table 1: MS/MS parameters for edoxaban, edoxaban-M4 and corresponding internal standard1 
















ESI+ Quantification 548.212 152.169 40 32 0.035 
ESI+ Confirmation 548.212 366.19 40 20 0.035 
Edoxaban-
M4 
ESI+ Quantification 521.162 321.176 38 24 0.035 
ESI+ Confirmation 521.162 339.12 38 18 0.035 
[2H6]-
edoxaban 
ESI+ Quantification 554.316 158.160 32 30 0.035 
ESI+ Confirmation 554.316 372.27 32 18 0.035 
 
                                                             
1 ESI+: Electrospray positive ionization mode 
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Table 2: Non-exhaustive list of drug-drug interactions with edoxaban2 
 CYP3A4/5 inducers CYP3A4/5 inhibitors Transporters inducers (P-gp, 
OATP, BCRP, OCT, …) 
Transporters inhibitors (P-gp, 
OATP, BCRP, OCT, …) 
Interactions Bosentan, carbamazepine, 
dabrafenib, efavirenz, 
enzalutamide, etravirine, 
lesinurad, perforate St John's 






Amiodarone, aprepitant, atazanavir, 
ceritinib, clarithromycin, cobicistat, 
crizotinib, darunavir, diltiazem, 
erythromycin, fluconazole, fluoxetine, 
fluvoxamine, fosamprenavir, 
fosaprepitant, idelalisib, imatinib, 
itraconazole, ivacaftor, ketoconazole, 
lapatinib, lopinavir, netupitant, nilotinib, 
olaparid, pazopanib, grapefruit / pomelo, 
piperaquine, posaconazole, ribociclib, 
ritonavir, roxithromycin, saquinavir, 
stiripentol, telaprevir, ticagrelor, 
tipranavir, verapamil, voriconazole 
Carbamazepine, dabrafenib, 




cabozantinib, carfilzomib, ceritinib, 
ciclosporin, clarithromycin, 
cobicistat, crizotinib, daclatasvir, 
diltiazem, eliglustat, erythromycin, 
glecaprevir, itraconazole, ivacaftor, 
ketoconazole, lapatinib, 
nicardipine, pibrentasvir, ponatinib, 
propafenone, quinidine, ribociclib, 
ritonavir, saquinavir, ticagrelor, 
vandetanib, velpatasvir, 






The induction of cytochrome 
P450 isoenzymes 3A4/5 leads 
to a decrease of edoxaban 
concentration vs an increase of 
edoxaban-M6 and -M8 
metabolites concentrations. 
The inhibition of cytochrome P450 
isoenzymes 3A4/5 leads to a stable of 
edoxaban concentration vs a decrease of 
normal edoxaban-M6 and -M8 
metabolites concentrations. Edoxaban-
M4 metabolite concentration tends to 
increase. 
The induction of transporters 
leads to an increase of edoxaban 
concentration and an increase of 
edoxaban-M4, -M6 and -M8 
metabolites concentrations. 
The inhibition of transporters leads 
to a decrease of edoxaban 
concentration and a decrease of 
edoxaban-M4, -M6 and -M8 
metabolites concentrations. 
 
                                                             
2 10. Parasrampuria, D.A. and K.E. Truitt, Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting 
Factor Xa. Clin Pharmacokinet, 2016. 55(6): p. 641-55. 24. CBIP, Centre Belge d’Information Pharmacothérapeutique - Bon usage des médicaments - Interactions des 
médicaments. 2018.  
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Supplementary table 1: Accuracy and precision for edoxaban and edoxaban-M43 
 Nominal concentration (ng/mL) 
Within-Run Accuracy (%) - 
Day 1 
Within-Run Accuracy (%) - 
Day 2 
Within-Run Accuracy (%) - 
Day 3 
Within-Run Accuracy (%) - 
Day 4 
Within-Run Accuracy (%) - 
Day 5 
Edoxaban 
3 -9 16 -1 5 -3 
10 -14 2 1 -4 4 
75 -2 7 5 1 9 
250 -3 1 13 -1 -2 
500 -7 -2 -1 3 -5 
Edoxaban-M4 
3 -22 7 4 6 2 
10 -13 -7 0 -3 -13 
75 -16 -4 -4 8 -3 
125 -11 -7 9 12 -6 
150 -13 -7 -4 7 -6 
 Nominal concentration (ng/mL) 
Within-Run Precision (%) - 
Day 1 
Within-Run Precision (%) - 
Day 2 
Within-Run Precision (%) - 
Day 3 
Within-Run Precision (%) - 
Day 4 
Within-Run Precision (%) - 
Day 5 
Edoxaban 
3 4 0 2 2 3 
10 0 3 2 2 2 
75 3 3 1 2 1 
250 1 2 0 1 2 
500 2 2 0 1 2 
Edoxaban-M4 
3 4 1 6 4 6 
10 0 4 3 2 3 
75 6 3 2 1 3 
125 1 1 0 0 1 
150 0 2 0 0 2 
 Nominal concentration (ng/mL) 
Between-Run Accuracy (%) - 
Edoxaban in NPP 
Within-Run Precision (%) - 
Edoxaban in NPP 
Between-Run Accuracy (%) - 
Edoxaban-M4 in NPP 
Within-Run Precision (%) - 
Edoxaban-M4 in NPP - 
Edoxaban 
3 2 2 - - - 
10 0 2 - - - 
75 4 2 - - - 
250 2 1 - - - 
500 -2 1 - - - 
Edoxaban-M4 
3 - - 0 4 - 
10 - - -7 3 - 
75 - - -3 3 - 
125 - - -1 1 - 
150 - - -5 1 - 
 
                                                             
3 Results are expressed as the mean of measured concentrations. 
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Figures 
Figure 1: Postulated edoxaban metabolism for active metabolites 4 
 
 
                                                             
4 CES1: carboxylesterase-1; CYP3A4/5: Cytochrome P450 isoenzyme 3A4/5 ; IC50: half-maximal inhibitory 
concentration; Cmax: maximum observed plasma drug concentration 
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Figure 3: Laboratory testing of edoxaban and expected plasma concentrations after therapeutic doses5  
 
                                                             
5 Red and blue lines represent plasma concentrations at peak and trough in NVAF and VTE, respectively. 
Orange boxes represent ranges of applicability of the corresponding test. ‡This represents the range of 
quantitation for sensitive reagents. Depending on the reagent, the sensitivity may be lower. aPTT, activated 
partial thromboplastin time; CMAX, maximum plasma concentration during the dosing interval; CTROUGH, 
minimum plasma concentration during the dosing interval; IQR, interquartile range; NVAF, non-valvular atrial 
fibrillation; PT, prothrombin time; VTE, venous thromboembolism. Notes: (i) Data on plasma concentration 
were extracted from Ruff et al. 20. Ruff, C.T., et al., Association between edoxaban dose, concentration, anti-
Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 
trial. The Lancet, 2015. 385(9984): p. 2288-2295. , Weitz et al. 22. Weitz, J.I., et al., Randomised, parallel-
group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin 
for stroke prevention in patients with atrial fibrillation. Thromb Haemost, 2010. 104(3): p. 633-41. and 
Verhamme et al. 21. Verhamme, P., et al., Dose reduction of edoxaban preserves efficacy and safety for the 
treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. 
Thromb Haemost, 2016. 116(4): p. 747-53.. 
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Supplementary Figures 
Supplementary figure 1: Gradient program for the mobile phase, with UPLC-grade water with 0.1% formic 





Supplementary figure 2: MRM chromatograms of edoxaban, edoxaban-M4 and [2H6]-edoxaban 
 
 
MRM chromatograms of [2H6]-edoxaban (12ng/mL), edoxaban (500ng/mL) and edoxaban-M4 (150ng/mL) using 
optimized MS and chromatographic conditions.  
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%Dev - Quadratic calibration curve of (A) edoxaban and (B) edoxaban-M4 in NPP with non-linear ponderation 
1/x. For edoxaban, red and green lines represent ranges of ±20% or ±15%, respectively. For edoxaban-M4, red 
and green lines represent ranges of ±25% or ±20%, respectively.  
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(A) Within-Run Accuracy (%) - Calibration curve of edoxaban in NPP. Red and green lines represent ranges of 
±20% or ±15%, respectively. (B) Between-Run Accuracy (%) - Calibration curve of edoxaban in NPP. Red and 
green lines represent ranges of ±20% or ±15%, respectively. 
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(A) Within-Run Accuracy (%) - Calibration curve of edoxaban-M4 in NPP. Red and green lines represent ranges 
of ±25% or ±20%, respectively. (B) Between-Run Accuracy (%) - Calibration curve of edoxaban-M4 in NPP. Red 
and green lines represent ranges of ±25% or ±20%, respectively. 
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(A) Within-Run Precision (%) - Calibration curve of edoxaban in NPP. Red and green lines represent ranges of 
±20% or ±15%, respectively. (B) Between-Run Precision (%) - Calibration curve of edoxaban in NPP. Red and 
green lines represent ranges of ±20% or ±15%, respectively. 
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(A) Within-Run Precision (%) - Calibration curve of edoxaban-M4 in NPP. Red and green lines represent ranges 
of ±25% or ±20%, respectively. (B) Between-Run Precision (%) - Calibration curve of edoxaban in NPP. Red and 
green lines represent ranges of ±25% or ±20%, respectively. 
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Supplementary figure 8: Selectivity 
Selectivity assessment aims to verify that the substance being measured is the intended analyte to minimize or 
avoid interference. The analyze of blank samples of the appropriate biological matrix from six individual sources 
did not highlight any interference at retention time of edoxaban, edoxaban-M4 and the internal standard 
(chromatograms were visually checked to assess interferences). According to the visual interpretation of these 
chromatograms, no interference at predicted retention times of edoxaban, M4 or IS occurs in individual plasma 
without these molecules of interest. 
 




Individual plasma 1 – No edoxaban – No edoxaban-M4 – No internal standard. 
 













Individual plasma 5 – No edoxaban – No edoxaban-M4 – No internal standard. 
 
 
Individual plasma 6 – No edoxaban – No edoxaban-M4 – No internal standard. 
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Supplementary figure 9: Representative chromatograms with retention times of apixaban, rivaroxaban, 
edoxaban, edoxaban-M4 and dabigatran 
 
 
 
 
 
